VTRS

Viatris Inc. [VTRS] Stock Forecast

Q: What is Viatris Inc. stock symbol ?

Viatris Inc. is a US stock, located in Canonsburg of Pa and trading under the symbol VTRS

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

VTRS Stock Summary

VTRS has more than 3 years of cash runway (44 months)

Earnings are expected to fall -100% next year

Unstable dividend track record

Top 10 Correlated ETFs

VTRS

Top 10 Correlated Stocks

VTRS

In the News

VTRS Financial details

Company Rating

Neutral

Market Cap

13.46B

Income

54.7M

Revenue

15.41B

Book val./share

17.05

Cash/share

0.9

Dividend

0.48

Dividend %

4.14%

Employees

38K

Optionable

Shortable

Yes

Earnings

06 May 2024

P/E

7.6

Forward P/E

PEG

-0.78

P/S

0.9

P/B

0.67

P/C

12.49

P/FCF

6.88

Quick Ratio

0.78

Current Ratio

1.6

Debt / Equity

0.89

LT Debt / Equity

0.79

EPS (TTM)

0.05

EPS next Y

EPS next Q

EPS this Y

-97.33%

EPS next Y

EPS next 5Y

EPS last 5Y

6.94%

Revenue last 5Y

5.99%

Revenue Q/Q

-2.98%

EPS Q/Q

-328.57%

SMA20

-8.33%

SMA50

-8.33%

SMA100

22.22%

Inst Own

74.02%

Inst Trans

-2.02%

ROA

ROE

ROC

0.03%

Gross Margin

40%

Oper. Margin

Profit Margin

12%

Payout

32%

Shs Outstand

Shs Float

Target Price

52W Range

8.74-13.62

52W High

-13.5%

52W Low

+40.56%

RSI

Rel Volume

0.31

Avg Volume

9.23M

Volume

2.86M

Perf Week

-2.81%

Perf Month

-8.28%

Perf Quarter

28.22%

Perf Half Y

19.25%

Beta

1.146

Volatility

0.1%, 0.31%

Prev Close

1.12%

Price

11.245

Change

1.12%

VTRS Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	22.3	19.87	14.8	13.42	12.81
Net income per share	0.03	-1.11	-1.05	1.71	0.05
Operating cash flow per share	3.5	2.05	2.5	2.44	2.33
Free cash flow per share	2.71	0.92	2.07	2.07	1.94
Cash per share	1.13	1.74	0.77	1.21	0.9
Book value per share	23.04	38.18	16.95	17.38	17.05
Tangible book value per share	-18.14	-31.73	-14.69	-9.87	-7.15
Share holders equity per share	23.04	38.18	16.95	17.38	17.05
Interest debt per share	25.67	44.26	18.39	16.39	15.65
Market cap	10.37B	11.27B	16.36B	13.49B	13B
Enterprise value	22.61B	36.53B	37.25B	31.51B	30.39B
P/E ratio	617	-16.82	-12.89	6.49	237.65
Price to sales ratio	0.9	0.94	0.91	0.83	0.85
POCF ratio	5.75	9.15	5.42	4.57	4.64
PFCF ratio	7.42	20.46	6.52	5.38	5.59
P/B Ratio	0.87	0.49	0.8	0.64	0.64
PTB ratio	0.87	0.49	0.8	0.64	0.64
EV to sales	1.97	3.06	2.08	1.94	1.98
Enterprise value over EBITDA	34.77	17.37	123.75	9.14	6.42
EV to operating cash flow	12.54	29.66	12.35	10.67	10.85
EV to free cash flow	16.18	66.35	14.85	12.55	13.07
Earnings yield	0	-0.06	-0.08	0.15	0
Free cash flow yield	0.13	0.05	0.15	0.19	0.18
Debt to equity	1.07	1.14	1.05	0.91	0.89
Debt to assets	0.41	0.42	0.39	0.39	0.38
Net debt to EBITDA	18.83	12.02	69.41	5.23	3.67
Current ratio	1.21	1.22	1.1	1.58	1.57
Interest coverage	-2.65	-0.23	-6.61	0.71	3.57
Income quality	107.36	-1.84	-2.38	1.42	51.18
Dividend Yield	0	0	0.02	0.04	0.04
Payout ratio	0.02	-0.01	-0.31	0.28	10.52
Sales general and administrative to revenue	0	0	0	0	0
Research and developement to revenue	0.06	0.05	0.04	0.04	0.05
Intangibles to total assets	0.68	0.68	0.7	0.66	0.61
Capex to operating cash flow	-0.23	-0.55	-0.17	-0.15	-0.17
Capex to revenue	-0.04	-0.06	-0.03	-0.03	-0.03
Capex to depreciation	-0.2	-0.31	-0.11	-0.15	-0.18
Stock based compensation to revenue	0	0.01	0.01	0.01	0.01
Graham number	4.11	30.94	20.01	25.9	4.18
ROIC	-0.01	0	-0.19	0.01	0.01
Return on tangible assets	0	-0.03	-0.08	0.12	0
Graham Net	-29.39	-51.87	-23.35	-18.86	-17.81
Working capital	1.19B	2.3B	1.02B	3.89B	4.45B
Tangible asset value	-9.36B	-19.08B	-17.76B	-11.96B	-8.58B
Net current asset value	-12.61B	-25.73B	-23.45B	-18.31B	-14.99B
Invested capital	1.07	1.14	1.05	0.91	0.89
Average receivables	2.97B	3.95B	4.56B	4.04B	3.93B
Average payables	1.09B	1.2B	1.2B	1.11B	1.27B
Average inventory	2.63B	4.07B	4.72B	3.75B	3.49B
Days sales outstanding	97.08	148	87.06	85.61	95.88
Days payables outstanding	50.98	60.27	31.31	43.28	57.21
Days of inventory on hand	128.22	245.08	117.93	131.54	143.69
Receivables turnover	3.76	2.47	4.19	4.26	3.81
Payables turnover	7.16	6.06	11.66	8.43	6.38
Inventory turnover	2.85	1.49	3.09	2.77	2.54
ROE	0	-0.03	-0.06	0.1	0
Capex per share	-0.79	-1.13	-0.42	-0.37	-0.4

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric	2022-12-31	2023-03-31	2023-06-30	2023-09-30	2023-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	3.2	3.1	3.27	3.29	3.19
Net income per share	0.83	0.19	0.22	0.28	-0.64
Operating cash flow per share	0.12	0.81	0.43	0.7	0.4
Free cash flow per share	-0.02	0.74	0.36	0.61	0.23
Cash per share	1.21	0.57	0.67	1.3	0.9
Book value per share	17.37	17.4	17.38	17.4	17.05
Tangible book value per share	-9.86	-10.27	-9.82	-8.91	-7.15
Share holders equity per share	17.37	17.4	17.38	17.4	17.05
Interest debt per share	16.01	15.57	15.62	15.44	15.3
Market cap	13.5B	11.57B	11.97B	11.83B	13B
Enterprise value	31.52B	29.64B	29.92B	28.9B	30.38B
P/E ratio	3.34	12.87	11.33	8.92	-4.24
Price to sales ratio	3.48	3.1	3.05	3	3.4
POCF ratio	94.68	11.91	23.24	14.18	27.11
PFCF ratio	-579.48	13.02	28.1	16.16	46.67
P/B Ratio	0.64	0.55	0.57	0.57	0.64
PTB ratio	0.64	0.55	0.57	0.57	0.64
EV to sales	8.13	7.95	7.63	7.33	7.94
Enterprise value over EBITDA	19.18	63.02	62.86	55.73	25.88
EV to operating cash flow	221.01	30.52	58.1	34.65	63.38
EV to free cash flow	-1.35K	33.35	70.24	39.48	109.1
Earnings yield	0.07	0.02	0.02	0.03	-0.06
Free cash flow yield	0	0.08	0.04	0.06	0.02
Debt to equity	0.91	0.89	0.89	0.88	0.89
Debt to assets	0.39	0.38	0.38	0.38	0.38
Net debt to EBITDA	10.96	38.43	37.72	32.92	14.81
Current ratio	1.58	1.58	1.5	1.6	1.57
Interest coverage	5.26	-1.77	2.57	3.19	3.62
Income quality	0.14	4.32	1.95	2.52	-0.63
Dividend Yield	0.01	0.01	0.01	0.01	0.01
Payout ratio	0.14	0.64	0.55	0.43	-0.19
Sales general and administrative to revenue	0	0	0	0	0
Research and developement to revenue	0.05	0.05	0.05	0.05	0.05
Intangibles to total assets	0.66	0.68	0.67	0.65	0.61
Capex to operating cash flow	-1.16	-0.08	-0.17	-0.12	-0.42
Capex to revenue	-0.04	-0.02	-0.02	-0.03	-0.05
Capex to depreciation	-0.19	-0.11	-0.13	-0.15	-0.31
Stock based compensation to revenue	0.01	0.01	0.01	0.01	0.01
Graham number	18.05	8.55	9.28	10.4	15.65
ROIC	0.01	0	0.01	0.01	0.01
Return on tangible assets	0.06	0.01	0.02	0.02	-0.04
Graham Net	-18.84	-19.32	-18.78	-18.07	-17.81
Working capital	3.89B	3.52B	3.25B	4.1B	4.45B
Tangible asset value	-11.96B	-12.35B	-11.77B	-10.69B	-8.58B
Net current asset value	-18.31B	-18.73B	-18.07B	-16.95B	-14.99B
Invested capital	0.91	0.89	0.89	0.88	0.89
Average receivables	3.57B	3.66B	3.55B	3.67B	3.89B
Average payables	974.6M	1.29B	1.36B	1.65B	1.69B
Average inventory	3.45B	3.59B	3.65B	3.66B	3.57B
Days sales outstanding	88.57	84.41	82.85	85.36	95.09
Days payables outstanding	40.06	58.25	51.02	79.54	56.16
Days of inventory on hand	121.74	150.8	141.88	146.84	141.05
Receivables turnover	1.02	1.07	1.09	1.05	0.95
Payables turnover	2.25	1.55	1.76	1.13	1.6
Inventory turnover	0.74	0.6	0.63	0.61	0.64
ROE	0.05	0.01	0.01	0.02	-0.04
Capex per share	-0.14	-0.07	-0.07	-0.09	-0.17

VTRS Dividend History

VTRS Frequently Asked Questions

What is Viatris Inc. stock symbol ?

Viatris Inc. is a US stock , located in Canonsburg of Pa and trading under the symbol VTRS

What is Viatris Inc. stock quote today ?

Viatris Inc. stock price is $11.245 today.

Is Viatris Inc. stock public?

Yes, Viatris Inc. is a publicly traded company.

Something similar

Top by Market Cap

BRH.DE

DHR-PB

NVDA

Company Profile

Volume Average 9.23M
Market Capitalization 13.46B
Employee 38K
CEO Mr. Scott Andrew Smith
Headquarters Canonsburg,PA,US
IPO Date 1980-03-17
Website https://www.viatris.com

Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides its medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as offers biosimilars franchises, including Fulphila, Ogivri, Hulio, and SEMGLEE. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.